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Abstract
Background: Assessing daily change in pain and related symptoms help in diagnosis, prognosis, and monitoring
response to treatment. However, such changes are infrequently assessed, and usually reviewed weeks or months
after the start of treatment. We therefore developed a smartphone application (Keele Pain Recorder) to record
information on the severity and impact of pain on daily life. Specifically, the study goal was to assess face, content
and construct validity of data collection using the Pain Recorder in primary care patients receiving new analgesic
prescriptions for musculoskeletal pain, as well as to assess its acceptability and clinical utility.
Methods: The app was developed with Keele’s Research User Group (RUG), a clinical advisory group (CAG) and
software developer for use on Android devices. The app recorded pain levels, interference, sleep disturbance,
analgesic use, mood and side effects. In a feasibility study, patients aged > 18 attending their general practitioner
(GP) with a painful musculoskeletal condition were recruited to use the app twice per day for 28 days. Face and
construct validity were assessed through baseline and post-study questionnaires (Spearman’s rank correlation
coefficient). Usability and acceptability were determined through post-study questionnaires, and patient, GP, RUG
and CAG interviews.
Results: An app was developed which was liked by both patients and GPs. It was felt that it offered the
opportunity for GPs to discuss pain control with their patients in a new way. All participants found the app easy to
use (it did not interfere with their activities) and results easy to interpret. Strong associations existed between the
first 3 days (Spearman r = 0.79) and last 3 days (r = 0.60) of pain levels and intensity scores on the app with the
validated questionnaires.
Conclusions: Collaborating with patient representatives and clinical stakeholders, we developed an app which can
be used to help clinicians and patients monitor painful musculoskeletal conditions in response to analgesic
prescribing. Recordings were accurate and valid, especially, for pain intensity ratings, and it was easy to use. Future
work needs to examine how pain trajectories can help manage changes in a patient’s condition, ultimately assisting
in self-management.
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Background
Annually, 15–20% of all adults attending general practice
present with musculoskeletal conditions [1]. Around
40% of these patients are prescribed analgesia during
their first consultation for musculoskeletal pain, half of
whom will receive a non-steroidal anti-inflammatory
drug (NSAID), and 29% a moderate to strong opioid
containing analgesic [2, 3]. The general practitioner’s
(GP’s) intention is to relieve their patient’s pain and the
decision to use analgesia, for example in low back pain,
is often based on the patient’s verbal report of their pain
and their personal analgesic preferences [4]. Any subse-
quent review of analgesic efficacy is similarly limited by
the GP relying on the patient’s reports of their pain pro-
gress, often quantified by asking patients to rate their
pain on a scale from 0 (no pain) to 10 (worst pain) [5].
However, this existing approach to pain monitoring fails
to account for the multiple dimensions of pain experi-
ence in relation to its onset (acute, or gradually devel-
oped over time), course over time (stable or highly
variable), severity, and impact on everyday life [6].
Obtaining more detailed pain experience information
could be an important and useful tool for clinical prac-
tice. For example, symptom trajectories have been
shown to help obtain an accurate diagnosis in headache
[7]; monitor the severity/impact of symptoms in asthma
or abnormal vaginal bleeding [8, 9]; or assess short-term
responses to treatment [10, 11]. Furthermore, informa-
tion on short-term symptom trajectories has the poten-
tial to provide important prognostic information, and is
likely to result in better long-term prediction of health
outcomes [12, 13].
Despite a wide variation in musculoskeletal pain tra-
jectories over time, early changes in painful symptoms
after prescribing an analgesic (such as an opioid) are not
routinely collected as part of musculoskeletal follow-up
assessments, which often take place several weeks or
even months later [14–16]. Monitoring of these changes
in response to opioids is very important, and now under-
pins current guidelines [17], especially since evidence for
the long-term effectiveness of opioids is lacking [18],
and there is an increasing recognition of the harms re-
lated to opioid use [19, 20]. Although many studies have
reported on the long-term (6–12months) outcomes of
musculoskeletal pain [12, 15], and investigated
long-term trajectories using repeated pain assessment
[15, 21–23], little is known about short-term pain trajec-
tories following primary care consultations, how they re-
late to long-term outcomes, and in what way they might
be used to support the primary care management of
musculoskeletal pain.
When pain trajectories are measured, data have often
been collected using paper diaries, which are cumber-
some, have low completion rates, and may be completed
retrospectively resulting in inaccurate and potentially
biased data [24–26]. In recent years alternative methods
for daily data collection have been proposed, including
the use of text messaging [27–29], palm top computers
[30], or Smartphone technology [31]. These approaches
are gaining popularity given the increasing use of Smart-
phones and particularly now with two thirds of British
adults owning one [32]. One systematic review identified
55 articles reporting the design, evaluation, or use of
smartphone-based software for healthcare professionals,
students, or patients. The authors highlight the increas-
ing use of Smartphone technology in healthcare and
their potential role in patient education, disease
self-management, and remote monitoring of patients
[33]. Limitations of Smartphone technology have also
been reported, most importantly the lack of personalised
feedback, usability issues (e.g. ease of data entry), and
poor integration of Smartphone data with electronic
health records [34, 35]. A systematic review of currently
downloadable pain monitoring apps has highlighted the
lack of scientific rigour used to ensure validity and reli-
ability with respect to pain measurement [36]. However,
where attention to validation has been robust, moderate
to high reliability and validity has been reported [37, 38].
Therefore, in this feasibility study, our aim was to:
1. develop a Smartphone Application (“Keele Pain
Recorder”) for use by patients with painful
musculoskeletal conditions to record daily
information on their pain severity and the impact of
pain on daily life.
2. assess the acceptability and clinical utility of the
Pain Recorder in terms of completion rates,
feasibility of its use, and its influence on GP
decision-making. Even if an app is found to have a
high level of validity in collecting data, its clinical
usefulness is only as good as its level of acceptability
to the user in day to day use [39]. It is therefore, as
part of any app development, essential to examine
how acceptable and useful to the user it is.
3. assess face and content validity and explore
construct validity of data collection using the Keele
Pain Recorder in musculoskeletal patients
presenting to primary care receiving new analgesic
prescriptions. We hypothesised that single Pain
Recorder items were highly correlated with
validated questionnaires measuring the same
domain of interest i.e. whether there was a strong
correlation between the Keele Pain Recorder scores
and questionnaire scores at baseline (day 1–3 for
the Pain Recorder) and follow-up (last 3 days for
the pain app), and between changes over time in
scores from the app and questionnaires (longitu-
dinal validity).
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4. assess the daily changes in pain and other symptoms
(short-term pain trajectories) for patients presenting
with a new episode of MSK pain during the first
4 weeks use of the Keele Pain Recorder. This is an
area of data collection that is important since
information on short-term symptom trajectories
might help in establishing the possible cause of symp-
toms (diagnosis) [7]; estimate the future course of a
condition (prognosis) [11, 40]; monitor the severity of
symptoms in patients with chronic conditions [9];
and assess early response to treatment (intervention)
[10, 11]. However, early changes in pain and other
symptoms are often not assessed until several weeks
or even months after the first consultation or start of
treatment [14–16], and development of the Keele
Pain Recorder (KPR) offers a clear opportunity to
examine these short-term trajectories in relation to
these areas of clinical assessment.
Methods
Development of the “pain recorder”
Design of the Pain Recorder
A workshop with 9 members of Keele University’s Insti-
tute for Primary Care and Health Sciences (IPCHS) Re-
search User Group (RUG) was organised to obtain the
views and opinions of people with experience of living
with chronic musculoskeletal pain to underpin the design
of the app. During the workshop, drafts (mock-ups) of
screens which might be potentially used for the Pain Re-
corder, and mock-up examples of possible pain trajectories
were presented to the RUG and a range of aspects of the
design and content of the proposed app were discussed.
These included: content and phrasing of questions regard-
ing pain and the impact of pain on everyday life to include
in the app; response options; appearance and functionality
of the app; content of help functions; how completion
rates could be optimised. The app developer as well as
members of the research team attended the workshop.
Consensus on the final content was achieved through the
use of electronic voting (using Turning Point) which
allowed the RUG to vote independently, ranking options
in order of preference [41]. The software calculates a
weighted response giving greater importance to higher
ranked options and thereby a clear indication of the
group’s overall choice on any aspect of the app discussed.
Discussions were audio-recorded, and written reports
drafted summarising feedback and advice from the RUG.
The app developer used the outcomes from this workshop
to develop a first alpha-version of the Pain Recorder.
Symptom measures
Though no formal reference to IMMPACT pain mea-
surements were made as this was a pain monitoring app
that was developed entirely by patients, the content of
the app reflects accurately those pain measurements
suggested as outcome measures in its recommendations
[42]. Consequently, the KPR records data on all domains
including pain intensity, analgesic use, the temporal na-
ture of pain, its effect on physical function, emotional
functioning (mood), pain trajectories assessing change,
and a record of adverse events.
All measures were derived by the RUG and clinical ad-
visory group (CAG). Pain recording was measured using a
standard numerical scale (0 = no pain, 10- worse pain im-
aginable) [43]. Pain impact was recorded in terms of inter-
ference of pain with activities at home, leisure, or work. A
scale of 1–5 where 0 = none and 5 = extremely was felt
most appropriate. This scale was developed by the RUG
amended from the SF36 [44]. If the patient had been
asleep in the previous 12 h this could be recorded and
whether their pain had interfered with sleep or not. This
was based on the Jenkins sleep scale [45]. For psychomet-
ric assessment the WHO-5 Well-Being Index assessing
cheerfulness was used, scored from 0 = none of the time,
to 5 = all of the time. The WHO-5 psychometric proper-
ties have been assessed and found to have adequate valid-
ity in screening for depression and in measuring
outcomes in clinical trials. It has good construct validity
as a unidimensional scale measuring well-being [46]. The
RUG voted against using the ‘pain bothersomeness’ ques-
tion commonly used in research [47].
A novel suggestion from the RUG related to assessing
medication adherence. Rather than recording the num-
ber of tablets taken, the group felt this was too complex
and time consuming and it was suggested the patient
record if they had taken their medication ‘as prescribed’,
‘less than’, or ‘more than’ recommended by their GP.
Finally, perceived side effects could be recorded at each
data entry point, or at any time the user wished to.
Face and content validity, beta-testing
The alpha version of the Pain Recorder was demonstrated,
including examples of downloads of pain recordings (tra-
jectories), during further workshops with our patient ad-
visory group (6 RUG members), and an additional clinical
advisory group (13 participants) of (academic) GPs, phys-
iotherapists, research nurses, primary care researchers, re-
search facilitators, and an IT manager. The following
issues were discussed: (a) content and wording of items in-
cluded in the Pain Recorder (face validity); (b) whether the
app incorporated all relevant aspects of pain interference
(content validity); (c) its utility for discussing symptoms
and medication use with patients (including adherence
and possible adverse effects); (d) its utility for supporting
decisions regarding treatment; and (e) opportunities for
using the app for research purposes. These meetings were
recorded, and written reports produced to summarise
comments and suggestions made by the group.
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Following these meetings, a beta version of the Pain
Recorder app suitable for Android smartphones/tablets
was developed by the study team based solely on the
recommendations from these groups.
The clinical advisory group (CAG) reviewed the app
and overall it was liked. It was felt that it offered the op-
portunity for GPs to discuss pain control with their pa-
tients in a new way that related medication use and
activity. An interesting point was made that in fact the
app might encourage adherence to decisions made on
pain medication use through its repeat recording re-
minder. It was agreed that all elements were clinically
useful and informative. They did not suggest further
changes to the context of the app.
Beta testing was undertaken over a four-week period
using 6 ‘Pain Recorder’ loaded tablets by study team
members, RUG members, and additional members of
the public of varying age, educational level, and familiar-
ity with smartphone technology. Following identification
of ‘bugs’, typographic errors and any elements of the
Pain Recorder that could cause confusion, the developer
produced the ‘Gold’ version of the app which was to be
used in the feasibility study.
Feasibility study
“Pain recorder” deployment and data collection
Study population Patients aged 18 years and over who
consulted at their general practice with a new episode of
musculoskeletal pain (defined as no consultation for
musculoskeletal conditions in the previous 3months)
were invited to take part in the study, if they were pre-
scribed a stronger class of analgesic (Non-Steroidal
Anti-Inflammatory Drug (NSAID) or strong opioid/opi-
oid combination medication containing more than 8mg
of codeine per tablet). Each GP system was programmed
to notify the GP when a suitable patient for the study
was identified through an appropriate prescription being
issued for one of the stronger analgesics or NSAIDs dur-
ing a consultation. This would also tag the patients rec-
ord identifying them as a suitable candidate for the
study with a searchable code. An automated message
would appear on the GP’s computer screen (a ‘pop-up’)
during the consultation and accordingly the GP could
invite the patient to the study. If the GP did not invite
the patient, weekly searches of the GPs computer system
identified these individuals through the code and they
were then invited to the study via a letter from the GP’s
surgery. Patients were excluded by the GP if they had
symptoms or signs indicative of pathology requiring ur-
gent medical attention; pain because of cancer or other
non-musculoskeletal condition; pain due to an acute in-
jury; inability to read and speak English; vulnerability
(e.g. dementia, terminal illness, severe mental health
problems); or travelling outside Europe/for longer than
30 days following the consultation. Eligible patients were
identified either during the consultation by the GP or
nurse practitioner, or after the consultation through
regular searches of consultation records. If the patient
was considered suitable, the patient was informed about
the study and provided with a participant information
sheet and referral form. Patients signing this form pro-
vided written consent to be contacted by the research
nurse. The GP/nurse practitioner prescribed pain medica-
tion as planned and continued to provide care as usual
during the study. Four general practices in North Stafford-
shire participated in the study. Ethical approval for this
study was obtained from the NRES Committee West Mid-
lands (REC Reference: 14/WM/1214). Patients involved in
the RUG group and workshops after data collection re-
ceived travelling expenses whilst the GPs involved and
users of the app in the study were not remunerated.
Data collection The research nurse contacted patients
interested in the research project, provided further infor-
mation about the study and made an appointment for a
baseline visit at the general practice. When signed in-
formed consent was obtained, participants completed a
baseline questionnaire, which included questions on
sociodemographic variables, lifestyle factors (alcohol use,
physical activity level); height and weight (for Body Mass
Index, BMI); history of musculoskeletal pain; use of an-
algesics; and baseline levels of pain intensity, pain inter-
ference, sleep, and mood using validated questionnaire
items. The baseline pain assessment recorded how long
the patient had been experiencing pain (less than 2 weeks
to more than 12month), and how long since they had
had no pain for more than a month. The main measure
relating to the app was pain severity in the last 24 h.
The research gave the participant’s a tablet pre-loaded
with the app for the duration of the study (4 weeks). The
Pain Recorder was demonstrated and set up for the par-
ticipant, who was then invited to enter recordings twice
daily for a period of 4 weeks.
An appointment was made for the participant to at-
tend a follow-up meeting with the research nurse and a
repeat consultation with the GP or nurse prescriber
1 month after receiving the Pain Recorder. During the
follow-up meeting the research nurse exported anon-
ymised data from the Pain Recorder as a password pro-
tected file and sent this to a secure NHS account,
accessible only by the GP, the research nurse and mem-
bers of the study team responsible for data management
and analysis. Graphical presentations of the data were
produced allowing the GP or nurse prescriber to discuss
the pain trajectories and response to prescribed pain
medication with the participant. The GPs and Nurse
practitioners received no formal training in how to
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interpret the graphs, or use them in their management.
This allowed us to examine how this novel data collec-
tion method would be used, or not used, in their day to
day practice. The participant was given a follow-up
questionnaire to be completed at home, including
follow-up questions on pain intensity, pain impact, sleep
and mood; course of pain over the past month, accept-
ability of the Pain Recorder, and the participants’ views
regarding the use of the Pain Recorder in the manage-
ment of their pain problem.
Acceptability, usability and clinical utility
Acceptability was assessed by descriptively summarising
Pain Recorder completion rates and responses by study
participants to questions regarding acceptability and use-
fulness in the follow-up questionnaire. Furthermore,
after completion of data collection a workshop was orga-
nised with study participants, which was facilitated by
members of our RUG, and semi-structured telephone in-
terviews were conducted with GPs from recruiting prac-
tices to discuss: (a) acceptability and feasibility of using
the Pain Recorder in clinical practice; (b) its utility for
discussing symptoms and medication use; (c) its utility
for supporting treatment decisions; (d) opportunities for
using the Pain Recorder for research purposes and (e) its
usability in terms of ease of use and interference with
patients’ daily activities. Usability is a key strength of any
smartphone application as it will ultimately determine
whether the app will be used in daily practice by pa-
tients. The full potential of any app is unlikely to be real-
ized unless the development and design take into
account usability [39]. The workshop group with users
of the app and RUG members followed an open forum.
The meetings were led by the RUG members who had
developed the content of the app using headline topics
that were then detailed using the thinking aloud tech-
nique. The agenda here was driven by patients, and re-
flects their experiences with no input from clinicians
such that the perspectives that evolved were personal to
users of the app. GPs interviews followed a specific set
of questions relating to their interaction with the user
and were purely their own opinion.
Workshop discussions and interviews were audio-re-
corded, and reports written to summarise responses to
questions and feedback provided during discussions.
Initial testing of construct validity
The pain trajectories generated by the app were down-
loaded and assessed by a second clinical advisory group
(CAG) to discuss the validity of recordings and deter-
mine if subgroups of participants with distinct patterns
of short term pain could be identified.
Construct validity was explored by comparing scores
for pain, sleep interruption, and mood collected at
baseline and one-month follow-up using validated ques-
tionnaires with entries on the Pain Recorder. The ques-
tionnaires used the same validated questions as those
used in the app, for example the WHO 5 well-being
index [46], a RUG adapted SF36 pain interference scale
and numerical pain rating scale [43]. Other validated
questions included in the questionnaires included pain
duration [48], pain trajectories [47], the Jenkin’s sleep
questionnaires [45], and physical activity (GPAQ) [49].
Statistical analysis Descriptive statistics were used to
characterise the study population, in terms of age, gen-
der, BMI, work status, pain characteristics, global health
and lifestyle factors. Potential subgroups of participants
with distinct patterns of short-term pain were identified
using blind voting. Nine members, including GPs, a pain
consultant, and physiotherapists were shown trajectories
of pain intensity, pain interference and mood for each
participant, with blind voting (Turning Point software)
being used to identify distinct trajectories and classify
participants according to these proposed subsets. Spear-
man’s correlation coefficient was used to assess the
strength of correlations between Pain Recorder scores
and questionnaire scores.
The ‘gold’ version of the Keele pain recorder app
The final version of the app had an alarm built in to re-
mind the user to record their pain experience at 8 am
and 8 pm. This could not be switched off, but the tablet/
phone could be if the patient did not wish to be dis-
turbed. There was an initial set up which was completed
with the research nurse to demonstrate the app. The pa-
tients personal ID was entered and in the set-up gender
and date of birth were recorded. Then each screen sub-
sequently appeared to ask in order about (1) Average
pain level in the last 24 h (2) Level of pain interference
or whether their pain disturbed sleep (3) Well-being
questions. At the set alarm times the patient would then
complete a similar set of questions (1) Average pain in
the last 12 h (2) Level of pain interference or had the
pain disturbed sleep (3) Well-being questions (4) Medi-
cation use (more than, less than or as prescribed) (5)
Did the patient feel they has side effects and if yes a
diary record of these could be entered (date and time re-
corded) (6) A screen asking if they wanted to record
anything else and if ‘yes’ they could enter a written note
(date and time recorded). The patient had the option to
enter a pain recording at any other time they wished
other than the pre-set times.
From the front page of the app patients could access a
help section for each page, giving advice on completing
the page, and this could be accessed from each page
when being competed as well. There was also in this sec-
tion a Frequently Asked Questions (FAQ) page which
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answered questions such as who to contact if there is a
problem, and who had access to the information re-
corded (Screenshot 8, Additional file 1). The last page of
the app advised patients if they felt severely unwell dur-
ing the study for any reason to contact urgent medical
help, ensure the tablet/phone was charged at least once
per day, if the patients missed a recording not to worry
and just complete the next.
After 1 month the patient returned to the Research
Nurse on the day of their appointment with their GP,
the graphical output from the app was downloaded and
passed to the GP for use in the consultation. The follow
up questionnaire was completed.
Results
Development and testing of the “pain recorder”
The ‘gold’ version of the Pain Recorder developed fol-
lowing the RUG and CAG workshops consisted of base-
line information; 6 questions to assess pain severity,
impact of pain on sleep or activities during the day,
mood, use of analgesics, and experience of adverse ef-
fects from analgesics; two help functions and a diary.
Screenshots are available in Additional file 1 (Screenshot
1–7). The RUG felt that it would not be onerous for
users to record data twice per day, every day (between 8
and 10, am and pm), and that an alarm would be helpful
to remind them.
The RUG felt that baseline information should be kept
to a minimum to improve completion rates and con-
sisted of age, gender and number of days per week
where the user was physically active for more than 30
min per day.
The RUG indicated that it was imperative instructions
for all sections were easily accessible and written in plain
English. It was also felt that a frequently asked questions
(FAQ) section would be helpful, and in this section in-
formation about contacting the study team should be
easily accessible.
One suggestion from the RUG was to link physical
activity, events, and other unusual activities to the re-
cordings as this might explain strong fluctuations in
pain trajectories. The conclusion was to allow patients
access to a diary which would record the date of entry
and in which such information, and any other that the
patient felt necessary, could be recorded and made
available to the GP.
Beta testing of the app revealed 38 ‘bugs’ and issues
that required remedy by the developer. The majority of
these were phraseology within the instructions and help
sections in the app, two major ‘bugs’ concerned func-
tionality (e.g. pressing ‘help’ on the side effects page led
to the diary and not the appropriate help page). Correc-
tion of these errors produced the final ‘Gold’ version
which was used in the feasibility study.
Finally, the study team and developer produced in-
structions for installing the Pain Recorder onto Smart-
phones, how to complete the app, and how to download
pain recordings for both the research nurses and pa-
tients to use. Downloads from the app could be copied
and pasted into GP medical records, printed for the GP
to use with the patient in a follow up consultation, as
well as emailed to the GP through a secure NHS.net ac-
count used by the research nurse.
Acceptability and clinical utility of the “pain recorder”
Completion rates
Five general practices (17 general practitioners, 2 nurse
practitioners) agreed to take part in the Keele Pain Re-
corder study, four of which recruited participants to the
study. The computer-generated message identifying po-
tential candidates for the study (pop-up) fired on 167 oc-
casions from which 27 suitable patients were invited to
the study and 25 consented to take part. Three withdrew
consent and one was lost to follow up when they did not
attend the baseline clinic. Of the 21 participants, 13
were females and 8 males, with a median age of 62 (IQR
50 to 70) years old (Table 1). Their median baseline pain
intensity was 6 (IQR: 4–7). Eighteen participants
attended the follow up clinic and returned the 1-month
follow-up questionnaire with three being lost to follow
up at this point. The participants entered 862 records,
53.1% in the morning, and 46.9% in the evening. Of
these records, 255 (30%) were entered during the first
week, 198 (23%) the second week, 198 (23%) the third
week, and 211 (24%) the fourth week. Median number
of records per participant were 23 in the morning and
22 in the evening over the recording period of 4 weeks,
indicating that recordings were made on 73.3% of days.
There was no association between completion rates and
gender or baseline pain intensity levels, but older partici-
pants tended to record more often than younger partici-
pants (Spearman correlation coefficient 0.47, p = 0.03).
Table 2 gives a summary of results from the 1-month
follow-up questionnaire (response n = 18; 86%). All partic-
ipants found the Pain Recorder easy to read, with the ma-
jority using the app daily or often. Six participants
reported that the use of the Pain Recorder had interfered
with their daily routine. The majority discussed the graphs
with their GP, and 11 reported that the GP showed inter-
est in the results. Most found the graphs easy to under-
stand, but opinions varied regarding their impact on
helping to discuss their pain or changes on medication.
No technical errors within the app occurred during
testing other than with two users where we were unable
to download the graphical output at the follow up nurse
research clinic, and these were later downloaded and
given directly to the GP who consulted the patient in
the following week.
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Workshop with participants
Two users attended the workshop with 2 RUG members
who developed the app. All study participants who
attended the participants’ meeting indicated that the
Pain Recorder had been very easy to use (‘child’s play’),
self-reporting that it took only 2 min on average to
complete (max 5min), and not interfering with daily life
or sleep. They had not needed the ‘Help Function’, nor
had required help from the study team or other people
(these two users were not those who reported it did
interfere or who had used the help function in the ques-
tionnaires). There was a discussion regarding the useful-
ness of the diary function: although this was considered
helpful to provide context to pain impacting on specific
activities, it was not needed on a daily basis. In terms of
utility the Pain Recorder was perceived as a tool to in-
form the GP how they had been managing their pain,
and it contributed to decisions by the GP regarding
medication changes. They felt the graphs were useful in
aiding the discussion and understanding of their pain.
They also indicated that the app did not directly influ-
ence their thoughts, feelings or actions related to mood,
pain interference, or medication usage. Important sug-
gestions for future use of the Pain Recorder included (1)
to make data recorded by users available to them in
graphical output at any time, and (2) to make the app a
‘real time’ monitoring tool which might offer advice on
treatment when required, either from protocols in the
app or from a medical professional.
Results from GP interviews
Results from semi-structured telephone interviews
(20–30 min each) with one GP from each of the four
recruiting practices showed that they felt the graphs
generated by the Pain Recorder were easy to inter-
pret, and most felt that the graphs were useful in
helping patients make choices about their use of
medication. GPs were confident that patients were happy
to bring these graphs to the consultation in the expect-
ation of discussing the results with their GP. Two GPs
however felt they could get the same information from
taking a history from the patient, and only one felt it influ-
enced their management strategy of the patients’ condi-
tions. One GP who did not use the graphs in the
consultation did not do so as they felt there was not
enough time to do this, so chose to ignore them. All four
GPs said they would recommend the Pain Recorder to pa-
tients for self-monitoring of their condition. In terms of
usefulness for research, two felt it would be more useful in
investigating and managing chronic rather than acute
pain, whilst one GP thought it had a place in trials of anal-
gesics to monitor patients’ response. They suggested that
in future iterations patients should be able to see trends in
their pain levels at any time they wished.
Table 1 Patients self-reported characteristics at baseline
Total participant (n = 21)
Demographic characteristics
Female, n (%) 13 (61.9)
Age, median (IQR) 62 (50, 70)
Body mass index, median (IQR) 27.8 (23.1, 32.0)
Alcohol drink days per week, median (IQR) 1 (0, 2)
Work status, n (%)
Working full-time in a paid job 7 (33.3)
Working part-time in a paid job 3 (14.3)
Employed but currently off sick 0 (0.0)
Housewife/husband 1 (4.8)
Unemployed due to pain condition 0 (0.0)






Intensity last 24 h (0–10 scale, median (IQR)) 6 (4, 7)
Location of current pain a, n (%)
Neck 2 (9.5)





Wrist or hand 6 (28.6)
Ankle or foot 2 (9.5)
Other 1 (4.8)
Pain duration of current episode
< 2 weeks 6 (28.6)
2–6 weeks 6 (28.6)
7–12 weeks 2 (9.5)
3–6 months 3 (14.3)
7–12 months 2 (9.5)
> 12months 2 (9.5)
General health, n (%)
Excellent 2 (9.5)





aSubgroups are not mutually exclusive as more than one location could
be selected
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Face and construct validity of the “pain recorder”
At both baseline and follow-up (4 weeks), the correla-
tions of pain intensity scoring between questionnaire
and Pain Recorder were very strong (Spearman’s correl-
ation coefficient ≥ 0.79, P < 0.0001). For pain interfer-
ence and mood, although weaker, significant or potential
correlations were still seen based on this relatively small
group of participants (Table 3). The correlation was even
weaker for sleep where the question examined related to
‘trouble staying asleep’. The number of entries in this
category were fewer with missing data and probably ac-
counts from some of the issues. Overall there were 862
responses in total. 840/862 (97.5%) responded with pre-
scribing information. Among the 862, in total 93(10.7%)
reported a side effect. Those using analgesia “as pre-
scribed” (n = 585) and “less than prescribed” (n = 186)
had similar side effect rates (10.0 and 11.9%, respect-
ively). Side effect rate appeared to be higher in “more
than prescribed”, but there were only 6 such records. No
significant difference of side effect was observed between
the three (P < 0.33).
Assessment of pain trajectories from the “pain recorder”
A wide variety of short-term pain trajectories were evi-
dent from recordings obtained from participants of the
feasibility study. The clinical advisory group proposed to
classify these into four main groups (Fig. 1): (a) recover-
ing (five participants); (b) fluctuating low to moderate
level of pain (eight participants); (c) deteriorating; (d)
unable to classify (two participants), when there was
more than 7 days of consecutive data missing.
This CAG visually inspected the temporal associations
between changes in daily pain score, mood, and pain
interference (for example Fig. 2). The subjective impres-
sion in this example was that the level of pain was
reflected in scores for mood score and interference of
pain on everyday activities, suggesting face validity of
the pain trajectories.
Discussion
In close collaboration with patient representatives and
clinical stakeholders, we developed a smartphone/tablet
app, which can be used to help clinicians and patients
monitor painful musculoskeletal conditions in response
to analgesic prescribing. Early testing in a small sample
of people consulting with musculoskeletal pain in
general practice showed promising results in terms of
face and content validity, acceptability, and clinical
usefulness.
Table 2 Summary of results from the follow-up questionnaire
n n n
Frequency of app use daily: 9 often: 9 sometimes/never: 0
Interference with daily routines No: 12 Yes: 6
Easy to read Yes: 18 No: 0
Use of HELP function No: 16 Yes: 2
Contact with research nurse No: 14 Yes: 4 (issues resolved)
Graphs discussed with GP Yes: 14 No: 3 Missing: 1
GP showed interest Yes: 11 No: 4 Missing: 2
Graphs difficult to understand Not at all: 8 Little bit: 3 Very: 1
Graphs helpful to discuss pain and impact Very: 4 Somewhat: 5 Not at all: 3
Impact of graphs on pain medication Stopped/changed: 2 Continued: 6 No influence: 6
Table 3 Correlation between Pain Recorder and questionnaire scores for assessing construct validity
Pair of variable Spearman’s correlation coefficient (r) P value
1. Baseline questionnaire pain intensity & Pain Recorder pain intensity first 1–3 a days (n = 20) 0.79 < 0.0001
2. Baseline questionnaire pain interference & Pain Recorder pain interference first 1–3 a days (n = 20) 0.60 0.005
3. Baseline questionnaire mood & Pain Recorder mood first 1–3 a days (n = 20) 0.27 0.27
4. Baseline questionnaire “staying asleep” & Pain Recorder “staying asleep” first 1–3 a days (n = 14) 0.22 0.45
5. Follow-up questionnaire pain intensity & Pain Recorder pain intensity last 1–3 a days (n = 18) 0.92 < 0.0001
6. Follow-up questionnaire pain interference & Pain Recorder pain interference last 1–3 a days (n = 18) 0.40 0.11
7. Follow-up questionnaire mood & Pain Recorder mood last 1–3 a days (n = 18) 0.15 0.56
8. Follow-up questionnaire “staying asleep” & Pain Recorder “staying asleep” last 1–3 a days (n = 15) 0.53 0.04
aAveraged score or category
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(a) (b)
(c) (d)
Fig. 1 Real life examples of different pain 4-week trajectories pain recorded by the app: (a): recovering; (b) fluctuating low to moderate pain; (c)
deteriorating; (d) unable to classify
(a) (b) (c)
Fig. 2 Real life changes in pain score recorded by the app (a) (1 = no pain, 10 = worst pain), mood (b) (1 = cheerful all the time 5 = none of the
time) and interference (c) (1 = not at all, 5 = all the time) over a 28 day period following initiation of a new prescription analgesic
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Despite there being more than 270 pain apps available
to download [50], there have been few studies that have
validated pain monitoring apps. Often existing apps are
designed by software engineers and there is little input
from patients and clinicians in the design and evaluation
of these apps [50, 51]. A recent review and Editorial
examining pain app design and use highlighted this fact,
particularly the finding that apps sometimes appear to
offer solutions to pain management with little thought
given to the content of the app being validly related to
clinical factors [31, 52]. This same review concluded that
the development of apps needs to be evidence-based
with rigorous evaluation of outcomes being important in
enhancing the understanding of the potential of these
apps [52]. Our study directly addresses this issue in that
the design of the Keele Pain Recorder was driven by
both patient and clinician experience and advice, whilst
its clinical usefulness, acceptability and validity was
assessed by several primary care clinicians in conjunc-
tion with the app users. One recent study has offered a
more vigorous examination of a pain monitoring App.
Suso-Ribera found that weekly monitoring of pain over a
30-day period found similarly high levels of compliance,
acceptability, ease of use and construct validity to the
KPR [53]. Jamison also found that a pain monitoring app
was acceptable to patients and easily utilised [54]. This
is encouraging as it suggests that pain monitoring apps
in varying forms are devices that patients will be willing
to engage with when managing their pain.
A series of iterative workshops and interviews with pa-
tients, clinicians and musculoskeletal researchers were
used to (i) discuss content and functionality of the app,
(ii) further improve the design of the app, and (iii) ex-
plore opinions regarding acceptability, validity, and use-
fulness. Patients confirmed that they felt discussing
recordings from the app helped with their GP’s under-
standing of their pain condition, whilst GPs considered
it useful in helping their patients make choices about
medication. Patients found the Keele Pain Recorder easy
to use, and the GP found the graphical output easy to
interpret. As in a study from the USA, both groups
found using a pain recorder app acceptable in clinical
practice [51].
The individual pain trajectories of patients varied
widely, reflecting wide differences in the impact and ex-
perience of pain, even over the course of only 1 month
after consulting in primary care. However, the trajector-
ies were determined through a visual analysis and a con-
sensus exercise amongst experienced clinicians rather
than using statistical methods. The number of trajector-
ies available to examine were too few and precluded this.
Therefore, it is possible that the trajectories determined
were subject to individual bias, however, agreement in
each case was by majority, and each participant had
extensive experience in the management of musculoskel-
etal pain. There may be value in assessing early symp-
tom trajectories in people with musculoskeletal
conditions, though further research is needed before any
potential clinical usefulness can be established. Many
prognostic models developed in studies of low back pain
have been shown to have limited predictive performance
[55], although some tools, such as the Start Back Screen-
ing Tool, have been extensively tested and are now also
available as a smartphone app. Although its predictive
performance has been confirmed in several populations,
one study showed that it was no better than clinical acu-
men in predicting low back pain outcomes [21]. One
reason for limited predictive performance of prognostic
tools may be that most are based on only a single assess-
ment of pain. In our study, the Keele Pain Recorder app
demonstrated three main short-term pain patterns:
improving, fluctuating or worsening, which reflect
those previously reported in patients with low back
pain [6, 22, 23]. Potentially the use of a smartphone/
tablet pain app might allow for more frequent and de-
tailed characterisation of pain trajectories shortly after
healthcare consultation. This, therefore, might be used
in the future to help develop more accurate predictive
models and early identification of patients likely to do well
(preventing unnecessary treatment) versus those who may
benefit from early, more intensive treatment [15].
An important limitation is the small sample size of the
feasibility study, which limits generalisability and precision
of our findings regarding construct validity. Though the
sample was small, we found a good correlation between
established and validated pain measures in the baseline
and follow-up questionnaires. However, there was no sig-
nificant correlation with interference, mood and sleep. It
is possible that in all these 3 domains (mood, interface
and sleep), this might have occurred because we averaged
results from the app over the first and last 3 days of the
study. Therefore, due to the potential variability in these
factors recorded in the app over this time, they may not
reflect those recordings in the baseline and follow-up
questionnaire. Small numbers in the study will also have
limited our power to detect any correlation. Further test-
ing of the Pain Recorder in larger groups of patients is
needed to more formally and quantitatively investigate
construct validity of the app, and to establish its clinical
utility for monitoring pain by investigating impact of its
use on clinical decision making and patient outcomes.
Additionally, we only tested the app amongst patients with
musculoskeletal pain, so the generalisability of its use in
other conditions such as headache or pelvic pain cannot
be assured. Similarly, our study focused on monitoring
pain following prescription of a stronger class of analge-
sics, but the app could also be used to study pain trajec-
tories following other types of treatments for pain.
Bedson et al. BMC Medical Informatics and Decision Making           (2019) 19:24 Page 10 of 13
Assessing acceptability and usability of the KPR pre-
sents problems in common with other smartphone apps
[56]. Both factors are interdependent, and it is likely that
testing these elements 1 week after starting using the
app would provide different results to our assessment
which was at 1 month of use. There may be issues for
users when they first use the software due them being un-
familiar with it, and therefore limit ease of use. Conse-
quently, acceptance of the app might be diminished.
However, after a month’s use, familiarity with the mechan-
ics of the software might improve usability for the pa-
tients. Equally though, with loss of novelty, the user might
lose interest in it and so its acceptance as a daily activity
might be lost. Future research might overcome these is-
sues through testing at both points in time to give a more
comprehensive view of an apps acceptability and usability.
Low completion rates were a limiting factor in this
study. This might have been compounded by the intru-
sion of the technology into daily life with it being per-
ceived as an interference in the user’s normal routine.
There are ways in which this might be overcome, for ex-
ample gamification has been shown to improve engage-
ment and retention in app use [57]. Equally if the app
had been used on the patient’s own mobile smartphone,
the more immediate access to this device (rather than a
tablet kept elsewhere) might have improved completion
rates. An additional limitation relates to the comparison
of the baseline and follow-up questionnaire pain scores
with those recorded in the app to determine how valid
these were. The most valid figure would have been to
equate the single baseline/follow-up figure with the first
and last day score in the app giving a direct contempor-
aneous comparison. However, we chose to use the initial
and final 3-day average of the study. This might have led
to errors in the comparison due to the potential variability
of the patient’s pain during that period when compared to
the single recording at baseline and follow-up. However,
due the possibility that we might recruit low total num-
bers to this novel research, we chose to use the 3-day aver-
age which would potentially give at least 1 record during
the 3 days. If we had only used the 1st or last day alone,
there might have been more missing values.
Two recordings could not be classified due to a lack of
consecutive data (> 7 days). This limitation was not over-
come by using reminder on the tablet and is likely to be
due to external circumstances, or interference of the
technology in the participants’ everyday life, which was
indicated to occur sometimes according to 6 of 18 par-
ticipants in the feasibility study. This may have been
compounded by the fact that the users did not have dir-
ect access to their pain graphs, which might have acted
in a positive way to reinforce use of the app. Concerns
have been expressed regarding the potential negative im-
pact of frequent pain reporting on physical health and
work productivity [58]. When asked specifically, partici-
pants reported that they felt using the app had not dir-
ectly influenced their thoughts, feelings or actions
related to mood, pain interference, or medication usage.
However, further research should investigate to what ex-
tent the use of the Keele Pain Recorder is associated
with consultation rates, healthcare resource use, and
changes in physical or mental health.
We developed secure methods for archiving, down-
loading and emailing pain trajectories from the Pain
Recorder to the GP and patient to be used in their
consultation. These methods will now be extended to
allow open-access to the Pain Recorder and support use
of the app on both Android and Apple phones or tablets
[59, 60]. Future research, however, needs to examine
how such data may be accessed in a ‘live’ format such
that GPs or other health care professionals may use in-
formation regarding pain trajectories to manage a pa-
tient’s condition when it deteriorates, for example
during an acute attack of gout or a flare of knee osteo-
arthritis. Research may also focus on the potential of
using the Keele Pain Recorder in self-management, such
that software might independently recognise when a pa-
tient is at risk of developing disabling pain, offering feed-
back and advice to the patient without the input of a
third party such as the GP. However, these devices will
require rigorous assessment to ensure the advice is safe,
relevant, and does not miss the possibility of ‘red-flag’
conditions such as cancer pain or other conditions (e.g.
inflammation) that need medical attention.
Conclusions
In conclusion, within this limited sample of users, we
have successfully developed the Keele Pain Recorder tab-
let app which both patients and clinicians considered
easy to use. Early testing shows promise in terms of val-
idity, acceptability and clinical usefulness, with clear pri-
orities identified for further testing and investigation of
its potential role and impact in the clinical and
self-management of musculoskeletal conditions and
other pain problems.
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